Skip to the content
Please enable JavaScript in your browser to complete this form.
Please complete the quiz
on or before 15 December 2021 (Wednesday).
We shall submit the CME accreditation for you after your submission of the quiz.
1. Which patient of the below is most likely to have the highest fracture risk?
*
a) Patient with a recent clinical or radiographic vertebral fracture
b) Patient with BMD T-score -2.0
and
no fracture history
c) Patient on oral bisphosphonate for 3 years
2. Which of the below best described patients who should be considered for initial treatment with Anabolic Agents?
*
a) Patients with 10-year major osteoporotic fracture risk at 10% at computed by FRAX
b) Patients who cannot tolerate oral bisphosphonates
c) Patients with very low BMD (T-score <-3)
3. Which of the below treatment sequence may produce the greatest BMD gain as demonstrated in clinical studies?
*
a) Bisphosphonates → Treatment holiday
b) Bisphosphonates → Anabolic agents
c) Anabolic agents → Denosumab
4. Which of the below description is correct when patients stopped anti-osteoporosis therapies (e.g. alendronate) without subsequent treatments?
*
a) BMD T-score of the patients would always remain unchanged
b) Patients would have higher risks of getting clinical fractures
c) Treatment holiday could be life-long and fracture risk would not increase
5. Which of the below osteoporosis management approaches is the most appropriate to prevent fractures in patients?
*
a) Osteoporosis should be treated as long as fracture risk remains high
b) Treatment holiday should be recommended after 3 years of anti-osteoporosis therapies, no matter which medication was prescribed
c) Evaluate patients’ fracture risks solely by BMD T-score
First Name
*
Last Name
*
Email Address
*
Submit
HK-07646-EVE-2021-Nov
Date of Approval: Nov 2021